MA
REGN icon

Montag & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Montag & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.4K Hold
137
– – ﹤0.01% 521
2026
Q1 		$106K Hold
137
– – ﹤0.01% 497
2025
Q4 		$106K Sell
137
-1
-0.7% -$679 ﹤0.01% 501
2025
Q3 		$77.3K Hold
138
– – ﹤0.01% 520
2025
Q2 		$72.2K Buy
138
+1
+0.7% +$558 ﹤0.01% 520
2025
Q1 		$86.8K Sell
137
-2
-1% -$1.38K ﹤0.01% 518
2024
Q4 		$98.9K Sell
139
-644
-82% -$540K ﹤0.01% 502
2024
Q3 		$823K Sell
783
-2
-0.3% -$2.23K 0.04% 265
2024
Q2 		$825K Sell
785
-162
-17% -$157K 0.04% 252
2024
Q1 		$911K Buy
947
+20
+2% +$19K 0.05% 255
2023
Q4 		$814K Buy
927
+774
+506% +$637K 0.05% 254
2023
Q3 		$126K Hold
153
– – 0.01% 439
2023
Q2 		$110K Sell
153
-2
-1% -$1.54K 0.01% 464
2023
Q1 		$127K Hold
155
– – 0.01% 440
2022
Q4 		$112K Buy
155
+25
+19% +$18.4K 0.01% 437
2022
Q3 		$90K Hold
130
– – 0.01% 453
2022
Q2 		$77K Hold
130
– – 0.01% 469
2022
Q1 		$91K Hold
130
– – ﹤0.01% 482
2021
Q4 		$82K Hold
130
– – ﹤0.01% 510
2021
Q3 		$79K Hold
130
– – ﹤0.01% 502
2021
Q2 		$73K Hold
130
– – ﹤0.01% 504
2021
Q1 		$62K Hold
130
– – ﹤0.01% 529
2020
Q4 		$63K Buy
+130
New +$70.2K ﹤0.01% 512

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Montag & Associates's REGN Position: Q2 2026 in Review

Montag & Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 137 shares worth $85.4K. The position accounts for ﹤0.01% of the portfolio, ranked #521.

Montag & Associates first reported a position in REGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $911K in Q1 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Montag & Associates held 137 shares of Regeneron Pharmaceuticals worth $85.4K as of Q2 2026.
  • Montag & Associates left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #521 holding.
  • Montag & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Montag & Associates's Regeneron Pharmaceuticals position peaked at $911K in Q1 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.